NovoCure Shares Decline Despite Q3 Earnings Beat and Upward Revenue Guidance
NovoCure (NVCR) shares fell approximately 7% during Thursday trading following the release of its third-quarter financial results. Although the company reported earnings that exceeded analyst expectations on both top and bottom lines, the market reacted negatively to the news. Despite the stock price decline, NovoCure raised its full-year revenue guidance for 2026 to a range of $736 million to $743 million, up from the previous projection of $710 million to $725 million. This updated outlook sits above the consensus estimate of approximately $726.12 million.
Tickers: $NVCR
Topics: earnings beat guidance raise revenue growth stock price movement